AptaBio Therapeutics Inc. (293780.KQ)
KRW 7740.0
(-3.73%)
KRW 7740.0
(-3.73%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -16.37 Billion KRW | -77.85% |
| 2022 | -9.48 Billion KRW | 16.4% |
| 2021 | -11.34 Billion KRW | -87.6% |
| 2020 | -6.04 Billion KRW | 15.45% |
| 2019 | -7.15 Billion KRW | -112.7% |
| 2018 | -3.36 Billion KRW | -64.59% |
| 2017 | -2.04 Billion KRW | -114.02% |
| 2016 | -954.42 Million KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.23 Billion KRW | -4.47% |
| 2024 Q1 | -3.09 Billion KRW | 49.01% |
| 2023 Q2 | -2.99 Billion KRW | 16.78% |
| 2023 Q3 | -4.2 Billion KRW | -40.57% |
| 2023 Q4 | -6.07 Billion KRW | -44.33% |
| 2023 Q1 | -3.59 Billion KRW | -35.16% |
| 2023 FY | -16.86 Billion KRW | -77.85% |
| 2022 FY | -9.48 Billion KRW | 16.4% |
| 2022 Q4 | -2.66 Billion KRW | -47.95% |
| 2022 Q3 | -1.79 Billion KRW | 37.66% |
| 2022 Q2 | -2.88 Billion KRW | -75.39% |
| 2022 Q1 | -1.64 Billion KRW | 44.13% |
| 2021 FY | -11.34 Billion KRW | -87.6% |
| 2021 Q3 | -2.65 Billion KRW | 20.56% |
| 2021 Q2 | -3.33 Billion KRW | -38.79% |
| 2021 Q1 | -2.4 Billion KRW | -25.99% |
| 2021 Q4 | -2.94 Billion KRW | -11.0% |
| 2020 Q1 | -1.63 Billion KRW | 23.67% |
| 2020 Q4 | -1.9 Billion KRW | -51.46% |
| 2020 FY | -6.04 Billion KRW | 15.45% |
| 2020 Q3 | -1.26 Billion KRW | -0.06% |
| 2020 Q2 | -1.26 Billion KRW | 22.89% |
| 2019 Q4 | -2.14 Billion KRW | 13.22% |
| 2019 FY | -7.15 Billion KRW | -112.7% |
| 2019 Q3 | -2.46 Billion KRW | -247.02% |
| 2019 Q2 | -710.81 Million KRW | 0.0% |
| 2018 Q4 | -2.38 Billion KRW | -845.94% |
| 2018 Q3 | 319.11 Million KRW | 144.14% |
| 2018 Q2 | -722.91 Million KRW | 0.0% |
| 2018 FY | -3.36 Billion KRW | -64.59% |
| 2017 FY | -2.04 Billion KRW | -114.02% |
| 2016 FY | -954.42 Million KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.54 Billion KRW | 16.214% |
| CMG Pharmaceutical Co., Ltd. | 5.72 Billion KRW | 385.991% |
| Celltrion Pharm, Inc. | 36.07 Billion KRW | 145.393% |
| Huons Global Co., Ltd. | 122.92 Billion KRW | 113.32% |
| DongKook Pharmaceutical Co., Ltd. | 66.87 Billion KRW | 124.484% |
| Enzychem Lifesciences Corporation | -14.35 Billion KRW | -14.052% |
| Humedix Co., Ltd. | 37.31 Billion KRW | 143.885% |
| Boditech Med Inc. | 33.44 Billion KRW | 148.959% |
| EuBiologics Co., Ltd. | 7.69 Billion KRW | 312.668% |
| FutureChem Co.,Ltd | -8.4 Billion KRW | -94.74% |
| Huons Co., Ltd. | 59.79 Billion KRW | 127.383% |
| BNC Korea Co., Ltd. | 10.81 Billion KRW | 251.345% |